Table 1.

Current Value Frameworks

Framework	Factors considered	Purpose	Costs measured?	Perspective
ASCO Framework	Net Health Benefit: Clinical Benefit (OS > PFS > RR), Toxicity, Extended Survival	Comparison of two regimens that have been reported in a randomized clinical trial	No	Patient
ESMO-MCBS	Magnitude of Clinical Benefit: Prognosis of Condition, Clinical Benefit (OS, PFS), Long-term Survival (HR, RR), Quality of Life, Toxicity	Comparison of magnitude of benefit of regimens with reported comparative research outcomes	No	Societal
NCCN Evidence Blocks	Efficacy, Safety, Quality of Evidence, Consistency of Evidence, Affordability	Visual representation of key factors that provide information about the value of the recommendations within the guidelines	Yes	Patient
MSKCC Drug Abacus	Efficacy, Cost Toxicity, Treatment Novelty, Costs of Development, Rarity of Disease, Population Burden of Condition	Intended to provide information regarding the proper pricing of new drugs in the market	Yes	Societal
ICER Value Framework	Incremental Cost - Effectiveness Ratio: $\frac{\mathrm{C}\mathrm{o}\mathrm{s}{\mathrm{t}}_{\mathrm{new}}-\mathrm{C}\mathrm{o}\mathrm{s}{\mathrm{t}}_{\mathrm{standard}}}{\mathrm{Effectivenes}{\mathrm{s}}_{\mathrm{new}}-\mathrm{Effectivenes}{\mathrm{s}}_{\mathrm{standard}}}$	Comparison of two treatments based on efficacy and cost	Yes	Societal

Abbreviations: OS Overall survival, PFS Progression-free survival, HR Hazard ratio, RR Response rate